Myeloma Patients Europe (MPE) has identified significant inequalities among patients’ access to myeloma clinical trials in Central and Eastern Europe (CEE) in a first-of-its-kind advocacy r
Sanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38 candidate isatuximab in multiple myeloma, already filed in the US and Europe. Headl
US biotech Mustang Bio says that an investigator-led trial of its CAR-T therapy for multiple myeloma – the first to target CS1 protein – has started recruiting patients.
Over the last decade, treatments for the blood cancer myeloma have come on in leaps and bounds – but it remains incurable and unpredictable for individual patients and clinicians.<
Research-based charities are taking on an ever-growing role in frontline clinical research, and Myeloma UK has just launched a ‘stratified medicine’ trial aimed at helping high risk patient